Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis

Sena,Paola; Mariani,Francesco; Benincasa,Marta; De Leon,Maurizio   Ponz; Di Gregorio,Carmela; Mancini,Stefano; Cavani,Francesco; Smargiassi,Alberto; Palumbo,Carla; Roncucci,Luca

doi:10.3892/or.2013.2846

Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis

Authors:
- Paola Sena
- Francesco Mariani
- Marta Benincasa
- Maurizio Ponz De Leon
- Carmela Di Gregorio
- Stefano Mancini
- Francesco Cavani
- Alberto Smargiassi
- Carla Palumbo
- Luca Roncucci
View Affiliations

Affiliations: Department of Biomedical, Metabolic and Neurosciences, Section of Human Morphology, University of Modena and Reggio Emilia, Modena, Italy, Department of Diagnostic and Clinical Medicine, and Public Health, University of Modena and Reggio Emilia, Modena, Italy, Department of Diagnosis Service and Legal Medicine, University of Modena and Reggio Emilia, Modena, Italy
Published online on: November 13, 2013 https://doi.org/10.3892/or.2013.2846
Pages: 103-110

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine whether BCL6 is expressed during malignant transformation of the large bowel and to assess whether, and to what extent, immunoreactivity is related to the different stages of neoplastic progression. Samples of normal colorectal mucosa (n=22), microadenomas (n=22) and colorectal cancer (n=22), were analyzed by immunohistochemistry, immunofluorescence coupled with confocal microscopy and western blotting. Our results clearly outlined the marked increase occurring in both intensity and density of BCL6 protein expression in the normal mucosa-microadenoma-carcinoma sequence. Immunohistochemistry and immunofluorescence analyses showed that BCL6 is expressed at low levels in normal mucosa and increases in microadenoma and in cancer with statistical significance. These results were confirmed by western blotting data. The increasing expression of BCL6 in human colorectal cancer development suggests the involvement of BCL6 in tumor progression, from the earliest stages of carcinogenesis with significant increase in cancer. The enhanced understanding of the biological role of BCL6, previously shown to exert a key role in lymphomagenesis, may lead to a re-evaluation of this protein and may highlight the importance of performing further studies in order to identify novel therapeutic targets for colorectal cancer.

View Figures

View References

1	Dent AL, Shaffer AL, Yu X, Allman D and Staudt LM: Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 276:589–592. 1997. View Article : Google Scholar : PubMed/NCBI
2	Basso K and Dalla-Favera R: Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. 247:172–183. 2012.
3	Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, Louie DC, Offit K, Chaganti RS and Dalla-Favera R: BCL-6 protein is expressed in germinal-center B cells. Blood. 86:45–53. 1995.PubMed/NCBI
4	Onizuka T, Moriyama M, Yamochi T, Kuroda T, Kazama A, Kanazawa N, Sato K, Kato T, Ota H and Mori S: BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood. 86:28–37. 1995.
5	Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
6	Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani R and Levy R: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 98:945–951. 2001.PubMed/NCBI
7	Dhordain P, Albagli O, Ansieau S, Koken MH, Deweindt C, Quief S, Lantoine D, Leutz A, Kerckaert JP and Leprince D: The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo. Oncogene. 11:2689–2697. 1995.PubMed/NCBI
8	Jardin F, Ruminy P, Bastard C and Tilly H: The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol. 55:73–83. 2007.
9	Okabe S, Fukuda T, Ishibashi K, Kojima S, Okada S, Hatano M, Ebara M, Saisho H and Tokuhisa T: BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor. Mol Cell Biol. 18:4235–4244. 1998.
10	Davies JM, Hawe N, Kabarowski J, Brand NJ, Leprince D, Dhordain P, Cook M, Morriss-Kay G and Zelent A: Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene. 18:365–375. 1999. View Article : Google Scholar : PubMed/NCBI
11	Dhordain P, Albagli O, Honore N, Guidez F, Lantoine D, Schmid M, The HD, Zelent A and Koken MH: Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. Oncogene. 19:6240–6250. 2000. View Article : Google Scholar : PubMed/NCBI
12	Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L, Venkitaraman A and Wagner S: BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene. 22:5572–5578. 2003. View Article : Google Scholar : PubMed/NCBI
13	Bos R, van Diest PJ, van der Groep P, Greijer AE, Hermsen MA, Heijnen I, Meijer GA, Baak JP, Pinedo HM, van der Wall E and Shvarts A: Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D₁ and hypoxia-inducible factor-1α (HIF-1α). Oncogene. 22:8948–8951. 2003. View Article : Google Scholar : PubMed/NCBI
14	Walters MP, McPhail ED, Law ME and Folpe AL: BCL-6 expression in mesenchymal tumours: an immunohistochemical and fluorescence in situ hybridisation study. J Clin Pathol. 64:866–869. 2011. View Article : Google Scholar : PubMed/NCBI
15	Suehiro Y and Hinoda Y: Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci. 99:1071–1076. 2008. View Article : Google Scholar : PubMed/NCBI
16	Di Gregorio C, Losi L, Fante R, Modica S, Ghidoni M, Pedroni M, Tamassia MG, Gafà L, Ponz de Leon M and Roncucci L: Histology of aberrant crypt foci in the human colon. Histopathology. 30:328–334. 1997.
17	Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L and De Pol A: Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif. 33:1–18. 2000. View Article : Google Scholar : PubMed/NCBI
18	Takayama T, Miyanishi K, Hayashi T, Kukitsu T, Takanashi K, Ishiwatari H, Kogawa T, Abe T and Niitsu Y: Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness. Clin Gastroenterol Hepatol. 3(Suppl 1): S42–S45. 2005. View Article : Google Scholar : PubMed/NCBI
19	Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A, Rossi G, Pedroni M, Luppi D, Santoro L, Monni S, Manenti A, Bertani A, Merighi A, Benatti P, Di Gregorio C and de Leon PM: Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 17:2291–2297. 2008. View Article : Google Scholar : PubMed/NCBI
20	Sena P, Roncucci L, Marzona L, Mariani F, Maffei S, Manenti A and De Pol A: Altered expression of apoptosis biomarkers in human colorectal microadenomas. Cancer Epidemiol Biomarkers Prev. 19:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
21	Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, Kataoka H, Kamiya T, Higashiyama S and Joh T: BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer. 100:1320–1329. 2009. View Article : Google Scholar
22	Roncucci L, Medline A and Bruce WR: Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev. 1:57–60. 1991.PubMed/NCBI
23	Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
24	Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/−colon carcinoma. Science. 275:1784–1787. 1997.
25	Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science. 275:1787–1790. 1997.
26	Pinto D and Clevers H: Wnt, stem cells and cancer in the intestine. Biol Cell. 97:185–196. 2005. View Article : Google Scholar : PubMed/NCBI
27	Saadi A, Shannon NB, Lao-Sirieix P, O’Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F and Fitzgerald RC: Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA. 107:2177–2182. 2010. View Article : Google Scholar
28	Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D and Torlakovic E: Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. Am J Clin Pathol. 121:34–42. 2004. View Article : Google Scholar : PubMed/NCBI
29	Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Eriksson S, Backlin C, Hagberg H, Rosenquist R and Enblad G: Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 18:1113–1120. 2005. View Article : Google Scholar : PubMed/NCBI
30	Levy O, Deangelis LM, Filippa DA, Panageas KS and Abrey LE: Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer. 112:151–156. 2008. View Article : Google Scholar : PubMed/NCBI